Antitumor effect of a newly synthesized celecoxib derivative encapsulated in liposome
- Authors
- Kim B.; Shin D.H.; Kim H.D.; Kim J.-S.
- Issue Date
- Apr-2013
- Publisher
- 한국약제학회
- Keywords
- Anticancer drugs; Caspase; Celecoxib; COX-2; Liposomes
- Citation
- Journal of Pharmaceutical Investigation, v.43, no.2, pp 101 - 106
- Pages
- 6
- Journal Title
- Journal of Pharmaceutical Investigation
- Volume
- 43
- Number
- 2
- Start Page
- 101
- End Page
- 106
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/6406
- DOI
- 10.1007/s40005-013-0057-4
- ISSN
- 2093-5552
2093-6214
- Abstract
- A new cyclooxygenase-2 inhibitor (code: PCX-3) was synthesized as a sodium salt form of celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and tested for its anticancer activity using human colon adenocarcinoma cells (HT-29) in vitro. Anti-proliferative effect of HT-29 cells by PCX-3 in DPPC/Chol liposomes was more effective than the free PCX-3 by 2-folds (IC30 = 125 μM vs. 227.5 μM). The same liposomal formulation of PCX-3 also showed a 2-fold increased effect than the free one both in DNA fragmentation and caspase activity of HT-29 cells at 19-743 μM and 37-371 μM ranges, respectively, suggesting apoptosis-based anti-proliferative effect. Down regulation of prostaglandin E2 level of HT-29 cells by the treatment of liposomal PCX-3 was more profound than its free form at 0.001-0.002 μM range. These data suggest that the liposomal formulation of this newly synthesized PCX-3 could be re-visited as a new anticancer or chemo-preventive agent in the future. © 2013 The Korean Society of Pharmaceutical Sciences and Technology.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.